I'm with you @edgescape In fact the examples you provided prompted me to check out what NEU has done previously and alas I find that they historically released positive news without any halt as evidenced by:

Neuren (NEU) – ASX Announcement 13 March 2023 FDA approval of DAYBUE™ (trofinetide) - the first approved treatment for Rett syndrome and....

Neuren (NEU) – ASX Announcement 23 January 2023 Prader-Willi syndrome IND for NNZ-2591 approved by FDA and....

Neuren (NEU) – ASX Announcement 13 September 2022 Rett Syndrome New Drug Application accepted for Priority Review by FDA

So in essence it's looking like negative news to me and because of the length of the halt....very bad news.

As a holder RL and SM I'm sure hoping I'm wrong!

Has there been some news released recently that's driving the share price or is it FOMO or....??

Interesting to see if the take-over speculation increases or simply fades away!

Comment on media speculation Melbourne, Australia:

Neuren Pharmaceuticals (ASX: NEU) notes an article published in the Australian newspaper, which stated “Neuren Pharmaceuticals is understood to have brought in a defence adviser after fielding buyer interest from US-based industry giants”.

Neuren appointed a corporate and strategic adviser several months ago. The appointment was a normal step in Neuren’s ongoing growth and development and not in response to any approaches from third parties. Media speculation to the contrary is unfounded.

I'll post these as they come in

News Summary*DJ Neuren Price Target Raised 68% to A$14.58/Share by Petra Capital

15 Mar 2023 10:24:11

Some new price targets released this morning as follows:

News Summary*DJ Neuren Target Price Raised 59% to A$13.67/Share by Bell Potter>NEU.AU

DJ Neuren Pharmaceuticals Target Price Raised 63% to A$18.29/Share by Wilsons>NEU.AU



Neuren (NEU) – ASX Announcement:

13 March 2023 FDA approval of DAYBUE™ (trofinetide) - the first approved treatment for Rett syndrome Highlights:

Acadia Pharmaceuticals announces US FDA approval of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older

First and only approved treatment for Rett syndrome

Acadia expects DAYBUE to be available by the end of April 2023

Rare Pediatric Disease Priority Review Voucher (PRV) granted in connection with approval

Neuren to receive US$40 million on first commercial sale, royalties on net sales, potential sales milestone payments and one third of the market value of the PRV